Myeloproliferative neoplasms, version 2.2018: Featured updates to the NCCN Guidelines Journal Article
| Authors: | Mesa, R. A.; Jamieson, C.; Bhatia, R.; Deininger, M. W.; Fletcher, C. D.; Gerds, A. T.; Gojo, I.; Gotlib, J.; Gundabolu, K.; Hobbs, G.; McMahon, B.; Mohan, S. R.; Oh, S.; Padron, E.; Papadantonakis, N.; Pancari, P.; Podoltsev, N.; Rampal, R.; Ranheim, E.; Reddy, V.; Rein, L. A. M.; Scott, B.; Snyder, D. S.; Stein, B. L.; Talpaz, M.; Verstovsek, S.; Wadleigh, M.; Wang, E. S.; Bergman, M. A.; Gregory, K. M.; Sundar, H. |
| Article Title: | Myeloproliferative neoplasms, version 2.2018: Featured updates to the NCCN Guidelines |
| Abstract: | Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET. © JNCCN - Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 10 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-10-01 |
| Start Page: | 1193 |
| End Page: | 1207 |
| Language: | English |
| DOI: | 10.6004/jnccn.2017.0157 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 November 2017 -- Source: Scopus |
